Impact of Cancer on Memory Functioning: Understanding Disorders Using Approaches in Neuropsychology and Neuroimaging
NCT ID: NCT01332916
Last Updated: 2014-04-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
60 participants
INTERVENTIONAL
2010-12-31
2014-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Memory Perception Assessment in Central/Non-central Nervous System Cancers
NCT03975959
Effect of Irradiation of the Cavernous Sinus and the Sellar Region on Autobiographical Memory
NCT02750371
Prospective Memory Imaging
NCT01638884
FluoroAv45 Imaging Research-in Alzheimer's Disease
NCT01325259
Optimization of MRI Sequences Used in the Study of Neurodegenerative Diseases
NCT05929144
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patients aged 45 and over group
patients aged 45 and over with breast cancer and should receive an adjuvant chemotherapy
cognitive tests and cerebral IRM
cognitive tests and cerebral IRM
healthy volunteers (controls) aged 45 and over
healthy volunteers (controls) aged 45 and over
cognitive tests and cerebral IRM
cognitive tests and cerebral IRM
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
cognitive tests and cerebral IRM
cognitive tests and cerebral IRM
cognitive tests and cerebral IRM
cognitive tests and cerebral IRM
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients from Grade 3 'end of primary schooling "minimum (scale Barbizet)
* Non-Metastatic Breast Cancer
* Adjuvant Chemotherapy: FEC, including Docetaxel Protocols
* No major cognitive impairment
* No previous neurological
* Lack of personality disorders and psychiatric disorders evolutionary
* Having signed the informed consent of study participation
* Women from the general population aged 45 and over, and matched in age and cultural level in patients
* Topics of Grade 3 'end of primary schooling "minimum (scale Barbizet)
* No prior cancer
* No major cognitive impairment
* No previous neurological
* Lack of personality disorders and psychiatric disorders evolutionary
* Participating in the IMAP Protocol No. ID-BCR: 2007-A00414-49 or IMAP+(n° ID RCB 2011-A01493-38)(see how the study below) have signed forms no objection and consent to study participation
Exclusion Criteria
* Metastatic
* Cancer of the breast other than primitive
* Patients with paraneoplastic syndrome
* Patients under 45 years
* Patients whose achievement is below level 3 'end of primary schooling "(scale Barbizet)
* Patients with adjuvant chemotherapy is associated with targeted therapy
* Patients who have received other cancer treatments (chemotherapy or radiotherapy brain)
* Contraindication to the implementation of an MRI (claustrophobia, metal objects in the body)
* disorders of higher functions existing in the administration of chemotherapy
* Neurologic earlier
* Pathology psychiatric evolutionary
* Refusal of participation
* Patients unable to meet the cognitive tests
* Drug use
* Heavy drinking
45 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Francois Baclesse
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Centre François Baclesse
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre de recherche CYCERON
Caen, Calvados, France
Centre François BACLESSE
Caen, Calvados, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CANMEM
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.